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GEP analysis validates high risk MDS and
acute myeloid leukemia post MDS mice
models and highlights novel dysregulated
pathways
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Abstract
Background: In spite of the recent discovery of genetic mutations in most myelodysplasic (MDS) patients, the
pathophysiology of these disorders still remains poorly understood, and only few in vivo models are available to
help unravel the disease.
Methods: We performed global specific gene expression profiling and functional pathway analysis in purified Sca1+
cells of two MDS transgenic mouse models that mimic human high-risk MDS (HR-MDS) and acute myeloid leukemia
(AML) post MDS, with NRASD12 and BCL2 transgenes under the control of different promoters MRP8NRASD12/tethBCL-2
or MRP8[NRASD12/hBCL-2], respectively.
Results: Analysis of dysregulated genes that were unique to the diseased HR-MDS and AML post MDS mice and not
their founder mice pointed first to pathways that had previously been reported in MDS patients, including DNA
replication/damage/repair, cell cycle, apoptosis, immune responses, and canonical Wnt pathways, further validating
these models at the gene expression level. Interestingly, pathways not previously reported in MDS were discovered.
These included dysregulated genes of noncanonical Wnt pathways and energy and lipid metabolisms. These
dysregulated genes were not only confirmed in a different independent set of BM and spleen Sca1+ cells from the
MDS mice but also in MDS CD34+ BM patient samples.
Conclusions: These two MDS models may thus provide useful preclinical models to target pathways previously
identified in MDS patients and to unravel novel pathways highlighted by this study.
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Background
Myelodysplastic syndrome (MDS) is an hematopoietic
stem cell disorder resulting in aberrant cell growth and
differentiation with enhanced genomic instability. The diag-
nosis of MDS is based on morphological features (dysplasia)
of the blood and bone marrow (BM) cells, cytopenias,
frequent excess of marrow blasts, and specific cytogenetic
abnormalities [1] such as deletions of chromosome 5, 7,
and trisomy 8. Transformation to acute myeloid leukemia
(AML) occurs in up to 40 % of MDS patients [2]. Major
advances have been acquired in the understanding of
MDS pathogenesis. Along with refined risk stratification
scores combining clinical and cytogenetic abnormalities,
whole-genome sequencing (WGS) and next-generation
sequencing (NGS) have identified mutations in genes
involved in signal transduction, splicing machinery, and
epigenetic or transcriptional pathways [3–11]. Gene ex-
pression profiling is a comprehensive approach taking
into account the majority of these altered pathways and
has contributed to a better definition of diagnosis and
prognosis in many diseases including MDS, when com-
bined with gene mutation or methylation data. [12–24].
Nevertheless, the survival of MDS patients, namely with
high-risk MDS remains extremely poor and therapy op-
tions scarce.
Animal models expressing MDS associated gene pheno-
copy either the MDS disease or more often its risk of
transformation to AML [25–27]. They have been instru-
mental to tackle other aspects of the disease such as the
involvement of the microenvironment [28], and we have
shown how they can be used to point at pathways to iden-
tify novel biomarkers and targeted therapies [29–35].
We therefore analyzed the gene expression pathways
and ontology functional groups in Sca1+ cells from two MDS
mouse models we have previously described [29, 30, 32–35].
These mice mimic human high-risk MDS (HR-MDS)
or AML post MDS depending on the promoter driving
the transgene (mutant NRASD12 or hBCL-2) expression
[32, 35]. BCL2 expression is required to drive the pheno-
type as inhibition of expression in conditional mice [32]
or inhibition by BH3 mimetic inhibitors [29] reverts the
phenotype. These models thus highlight the concept of
non-oncogene addiction [36] where cells bearing the
NRASD12 mutation require the BCL2 expression for sur-
vival and expansion. We have previously shown in these
mice a concomitant increase in reactive oxygen species
(ROS) with disease progression with a stepwise increase in
the frequency of DNA damage leading to an increased
frequency of error-prone repair of double-strand breaks
(DSB) by nonhomologous end-joining [35]. The observed
DNA damage and error-prone repair was decreased or re-
versed in vivo by N-acetyl cysteine antioxidant treatment
[35], stressing the relevance of these mice models to relate
genotype/phenotype to translational research. These
models have already allowed to identify novel biomarkers
of the disease in MDS patients such as the RAS:BCL-2
complex that links its localization at the plasma mem-
brane or the mitochondria with the apoptosis features
[30] and activates signaling protein profiles correlated
with disease and progression to AML [29]. Both diseases
are transplantable using BM or spleen cells from the dis-
eased mice, and both transgenes are expressed at the stem
cell level (Sca1+ compartment) [32]. Sca1− spleen cells
had a much longer latency period before developing
disease (Fig. 1e).
In this study, we found that the majority of the MDS-
dysregulated pathways that were unique to the MDS mice
and not the founder mice were close to those reported in
human MDS patients, underscoring the relevance of these
two mice models as preclinical models.
Results and discussion
Gene expression profile of the HR-MDS model
Establishment and characteristics of the HR-MDS model
are summarized in Fig. 1a–e. It is obtained by crossing
two single transgenic mice, expressing two human genes
known to be implicated in MDS, mutated NRASD12
and BCL2 (Fig. 1a). The clinical and biological features
of these transgenic mice have already been described
[29, 30, 32–35], and the co-expression of the two trans-
genes is required to establish the HR-MDS disease and
impact on survival, stressing the non-oncogenic addictive
effect of the BCL2 expression (Fig. 1b). The main charac-
teristics are pancytopenia, dysplasia, small percentage of
blasts in the spleen and bone marrow (BM) (Fig. 1a, c),
and increased apoptosis in the liver and spleen tissues
by TUNEL [29] or by whole body SPECT using 99Tc-
Annexin [29] (Fig. 1d). The model has been validated to
mimic the clinical (survival, response to treatment) and
biological features of HR-MDS in patients [29, 30, 32–35].
A novel biomarker, the NRASD12 and BCL2 plasma
membrane complex, correlates with apoptosis in spleen
and BM cells in the HR-MDS mice [32] and with apop-
tosis and low blast counts in MDS patients [30] under-
scoring the relevance of this model to study human
MDS.
Thus, to further exploit and complete the description
of this HR-MDS model, we performed gene expression
profile (GEP) analysis. GEP analysis was performed on
RNA extracted from Sca1+ cells from HR-MDS mice, the
founder mice (tethBCL2 and MRP8NRASD12) and normal
FVB/N mice (Fig. 2a–c). Sca1+ spleen cells were chosen
as we have shown that purified Sca1+ cells (from either
the spleen or the BM of HR-MDS mice) (Fig. 1e) [32] can
initiate the disease when transplanted in lethally irradiated
syngenic FVB/N mice, and the spleen of these mice yields
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more cells than the bone marrow, a prerequisite for both
RNA quality and quantity for the subsequent analyses. GEP
results were however validated on both spleen and bone
marrow samples (Figs. 2e and 4). Compared to normal
FVB/N mice, 1641 genes were significantly dysregulated in
HR-MDS mice, 1008 in the founder tethBCL2 mice and
2232 in the MRP8NRASD12 mice. Fifty-six percent of these
dysregulated genes were common and with similar levels of
expression between the HR-MDS mice and its founders
(MRP8NRASD12 and tethBCL2) and were not further ana-
lyzed in this study (Fig. 2a and Additional file 1: Table S1).
Gene set enrichment analysis (GSEA) was performed with
the 1641 genes significantly dysregulated in HR-MDS
mice compared to normal FVB/N mice, highlighting
enrichment in cell metabolism (energy; lipid metabolism),
cellular processes (DNA repair, cell cycle), angiogenesis,
signal transduction, and immune system (Table 1 and
Additional file 2: Figure S1A).
To select differentially expressed pathways implicated
in the initiation or maintenance of the disease, we focused
our study on a Database for Annotation, Visualization and
Integrated Discovery (DAVID) GEP analysis performed on
the 699 dysregulated genes that were unique to the HR-
MDS mice (Fig. 2a and Additional file 1: Table S2) and the
few dysregulated genes (n = 16) that were differentially
expressed (i.e., upregulated in the HR-MDS and downreg-
ulated in the founder mice and vice versa) (Fig. 2d and
Additional file 1: Table S3). Kyoto Encyclopedia of
Genes and Genomes (KEGG) pathway analysis was per-
formed using DAVID. The results are detailed in the
Fig. 1 a Schematic representation of the HR-MDS mouse model. The characteristics of this model have previously been published [24-26;29]. b Decrease
of the HR-MDS mice survival compared to its single transgenic mice founders, MRP8NRASD12 and tethBCL-2 transgenic mice; c Increased level
of Lin-Sca1+-cKit+ (LSK) cells in the BM; d Increased apoptosis in the liver and spleen seen by whole body SPECT using 99Tc-Annexin (liver
and spleen region located above the kidneys); e The disease can be transplanted in normal FVB/N irradiated syngeneic mice with either the
Sca1+ cells of the spleen or BM of the HR-MDS mice resulting in 15 % blast infiltration in the BM blasts as in HR-MDS mice[24-26;29]
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Fig. 2 a Venn diagrams of co-expressed and uniquely dysregulated genes compared to control FVB/N mice in the HR-MDS, MRP8NRASD12, and
tethBCL-2 transgenic mice; b Heat map of the down- and upregulated genes performed on the Sca1+ cells of HR-MDS (n = 3) compared to control
FVB/N (n = 3) mice; c Distribution in % of the significantly dysregulated genes in the KEGG David annotation pathways; d Analysis of the differentially
expressed genes (i.e., upregulated in the HR-MDS transgenic mice and downregulated in the founder mice and vice versa). Genes in regular font are
expressed at lower levels and genes in bold font are expressed in higher levels. Examples of microarray data are shown for each intersection;
e Validation of microarray data. qRT-PCR fold change of angpt1 and abcb4 gene expression in the BM and spleen cells of a different set of
HR-MDS mice
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Additional file 1: Tables S4–S14. The most significantly
dysregulated genes were distributed into eight pathways
(Fig. 2c). These dysregulated pathways included gene pro-
cessing (namely DNA-RNA-protein processing) (Additional
file 1: Table S4), cellular processes (DNA repair, cell cycle,
survival/apoptosis) (Additional file 1: Tables S5–S7), signal
transduction (Additional file 1: Tables S8 and S9), intracel-
lular trafficking and membrane transporters (Additional
file 1: Table S10), and immune system (Additional file 1:
Table S11). Finally, around 38 % of dysregulated path-
ways concerned various pathways but with less genes in-
volved per pathway including energy and lipid metabolisms
(Additional file 1: Table S12), and epigenetic/splicing path-
ways (Additional file 1: Table S13)
Of the ten most significantly upregulated pathways
(Table 2), the pathway ranking first concerned genes of
the PSM family of the proteasome, namely genes coding
for different components of 26S. Increase in proteasome
activity has been reported in MDS patients, and various
studies have shown the potential benefit of combining
an inhibitor of proteasome, bortezomid, with conventional
MDS therapy [37, 38]. Equally significantly upregulated
were genes coding for cell metabolism (energy and lipids)
and the cell cycle/checkpoints/DNA repair. Genes coding
for components of the major complexes of the mitochon-
drial electron transport chain were also significantly up-
regulated (Fig. 3a). These included genes of complex I:
NADH deshydrogenase, complex IV: cytochrome c oxidase,
and complex V: ATPase (confirmed by quantitative reverse
transcription-PCR (qRT-PCR) in the BM and spleen cells
of HR-MDS mice Fig. 4). Oxidative phosphorylation is the
metabolic pathway in which mitochondria produce
ATP required by proliferating cells. Oxidative metabol-
ism also produces reactive oxygen species (ROS) such
as superoxide and hydrogen peroxide, leading to propa-
gation of free radicals, enhancement of antioxidant
pathways but also DNA damage. Genes of the ROS/
antioxidant pathways (such as Txn1, Gpx1, Cebpα) were
not significantly dysregulated in the HR-MDS mice com-
pared to the founder mice (Additional file 1: Table S14),
whereas cell cycle checkpoints, DNA damage/repair
genes were significantly upregulated (i.e., mad2l1, cdc25a,
mdm2, chek2, rad54b, brca1, fancm (Table 2, Additional
file 1: Tables S5 and S7). These pathways and genes have
also been shown altered in some GEP studies of MDS pa-
tients [12, 16]. Amongst the lipid metabolism upregulated
genes figured both those of ether lipid metabolism and
glycosphingolipid biosynthesis. Though increase of acyl-
glycerophospholipids and ether lipid metabolism have
been reported in cancers, (confirmed by qRT-PCR in
the BM and spleen cells of HR-MDS mice Fig. 4) with
loss of tumorigenicity when efficiently targeted [39], lit-
tle is known regarding MDS patients.
A survival/apoptosis pathway showed a significant
downregulation of genes coding for inhibitors of apop-
tosis (naip, tnfaip3, and madk9) in line with the apoptosis
observed in this HR-MDS model [29, 30, 32]. Downregu-
lation of genes of the PI3K family (class II) and Pten was
also significantly downregulated (Table 3). While Pten is a
well-known tumor suppressor, few reports link it with
MDS [40, 41]. Class II PI3K proteins are involved in the
translocation of proteins to the cell membrane and have
been shown instrumental in Shh signaling, a pathway im-
plicated in the relation of stem cell with its environment
[42]. Moreover, two other downregulated pathways in-
cluded genes coding for socs4, a member of the suppressor
of cytokine signaling family (confirmed by qRT-PCR in
the BM and spleen cells of HR-MDS mice Fig. 4), and reg-
ulators of the immune response such as CD19 and CD40,
also reported to be decreased in MDS [20, 22, 43]
When we separately studied the 16 genes that were
differentially expressed between the HR-MDS mice and
its founder single transgenic mice (i.e., upregulated in
the HR-MDS and downregulated in the founders or vice
versa), we found that the majority (14 out of 16) of these
differentially regulated genes were between the HR-MDS
and the founder tethBCL-2 mice (Fig. 2d and Additional
file 1: Table S3). The most significantly differentially dys-
regulated gene was angiopoietin, Angpt1, upregulated in
the HR-MDS mice (confirmed by qRT-PCR in the BM
and spleen cells of HR-MDS mice and CD34+ from
Table 1 Summary of the top pathways highlighted by GSEA on
the total differentially expressed genes
HR-MDS versus FVB/N AML post MDS versus FVB/N
Adipogenesis Adipogenesis
Androgen response Allograft rejection
Angiogenesis Androgen response
Bile acid metabolism Apical junction
Coagulation Bile acid metabolism
Complement Cholesterol homeostasis
E2F targets Coagulation
Estrogen response late Complement
Fatty acid metabolism E2F targets
G2M checkpoint epitheliall mesenchymal transition
Glycolysis G2M checkpoint
Kras signaling Glycolysis
Mitotic spindle Hedgehog-signaling
mTORC1 signaling Mitotic spindle
Myc targets Oxidative phosphorylation
Oxidative phosphorylation Pancreas beta cells
UV response-dn Spermatogenesis
Xenobiotic metabolism Xenobiotic metabolism
Italicized data indicate pathways in common between the two models; Bold
data indicate similar pathways found in the « unique » genes
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MDS patients Figs. 2e and 4). Angiogenesis in MDS has
been described, and some of the efficacy of Lenalido-
mide is related to its anti-angiogenic effect [44, 45]. The
other dysregulated genes were linked to gene processing
with transcription regulation genes such as Zbtb10 (a
Zinc finger/POZ domain gene), the Mms22l gene (a
stabilizer of the NFKB-like enhancer), the Rgl1 gene (the
Ral guanine nucleotide dissociation stimulator involved
in Ras and Ral signaling [46]), the Lrrc41 gene coding
for a substrate of RhoBTB-dependent cullin 3 ubiquitin
ligase complexes [47], and the Baiap2l1 gene that modu-
lates MDM2-mediated p53 low-level ubiquitination. This
latter gene is dysregulated in myelofibrosis and a fusion
partner of Fgfr3 in AML [48] membrane transporters
with an increased expression of the P-glycoprotein gene
(Abcb4-Mdr3) in the HR-MDS mice, gene linked to drug
resistance in MDS [49] (confirmed by qRT-PCR in the
BM and spleen cells of HR-MDS mice Fig. 4), cytokine
signaling (Socs4, and Rfx5, a regulatory factor for major
histocompatibility complex, altered in primary MHCI
deficiency [50]) and cell adhesion with the Troap gene
coding for the trophin-associated protein involved in
cell adhesion complexes [51]. Only one gene, Sumo2
(coding for a SUMO ligase) was significantly differentially
expressed (upregulated) between the HR-MDS mice
and its founder MRP8NRASD12 mice; SUMOylation is a
major post translation modification of key proteins in-
volved in cell control and carcinogenesis [52]. Finally,
only one gene, Tmem181a, was differentially expressed
between HR-MDS and its two founders, MRP8NRASD12
and tethBCL-2 mice (upregulated in the founders and
downregulated in HR-MDS mice). The function of
Tmem181a is still not fully defined; it is a transmem-
brane protein with a conserved domain of Wnt binding
factor required for Wnt secretion MIG-14 [53]. Abnor-
malities in the microenvironment and Wnt signaling
may well relate to our current knowledge of MDS dis-
ease initiation and/or maintenance [54].
Table 2 Top regulated pathways in the list of upregulated genes in HR-MDS mice
Functional pathway KEGG database n Up P value Upregulated genesa
Genetic information processing Proteasome 7 4.3E-04 PSMD14, PSMD12, PSMC4, PSMA5, PSMD2, POMP, PSME4
PSMD14, PSMD12, PSMC4, PSMA5, PSMD2, PSME4 : PSM family
(proteasome 26S subunit)
POMP: proteasome maturation protein
Energy Metabolism Oxidative phosphorylation 10 2.0E-03 NDUFB3, NDUFV2, ATP5C1, COX4I2, COX4I1, VDAC2, VDAC3,
ATP5J, SLC25A4, PPID
NDUFB3, NDUFV2: NADH Ubiquinone oxido reductase
ATP5C1, ATP5J: one of the subunits of mitochondria APTase
VDAC2, VDAC3: voltage dependent anion channel.
COX4I2, COX4I1cytochrome c oxidase subunit 4
SLC25A4: SOLUTE CARRIER FAMILY 25 mitochondrial ADP/ATP translocator
PPID: peptidylprolyl isomerase D
Lipid metabolismEther lipid metabolism 4 3.7E-02 PAFAH1B3, AGPAT4, PPAP2A, CHPT1
PAFAH1B3: platelet-activating factor acetylhydrolase 1b, catalytic subunit 3
AGPAT4: 1-acylglycerol-3-phosphate O-acyltransferase 4
PPAP2A: Phosphatidic Acid Phosphatase 2a
CHPT1: choline phosphor transferase 1
Lipid metabolism Glycosphingolipid biosynthesis 3 3.9E-02 SLC33A1, HEXB, GLB1
SLC33A1: solute carrier family 33 (acetyl-CoA transporter)
HEXB: hexosaminidase B (beta polypeptide)
GLB1 : Galactosidase, beta 1
Cellular processesCell cycle 7 5.4E-02 MAD2L1, CCNH, SKP2, MDM2, CHEK2, CDC25A, BUB3
MAD2L1, mitotic spindle assembly checkpoint (interacts with BUB1)
CCNH: cyclin H; SKP2 : S-phase kinase-associated protein 2
MDM2: mouse double minute 2 homolog (E3 ubiquitin-protein ligase);
CHEK2: checkpoint
BUB3: budding uninhibited by benzimidazole (checkpoint protein )
aGene card nomenclature
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Gene expression profile of the AML post MDS model
The same GEP and functional annotation studies were
performed in the AML post MDS model. The character-
istics of the AML post MDS model are summarized in
Fig. 5. The only difference in the establishment of the
AML post MDS mice compared to that of the HR-MDS
mice is the founder BCL2 mice where the promoter
driving the expression of the BCL2 transgene is MRP8
(Fig. 5a). The AML post MDS mice have been described
with the HR-MDS mice [29, 30, 32–35]. The co-
expression of the two transgenes is required to establish
the HR-MDS disease and impacts on survival (Fig. 5b).
The AML post MDS mice present features of AML with
major infiltration of blasts in the BM (Fig. 5a) and spleen,
Fig. 3 Schematic representation of dysregulated energy metabolism pathways. Dysregulated pathways are noted in red, if upregulated, and in
green, if downregulated. a HR-MDS; b AML post MDS
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a significant increase of immature cells Lin−Sca1+ckit+
(LSK) cells in the BM (Fig. 5c) and absence of apoptosis
by Tunel assay [29] and 99Tc-Annexin SPECT imaging
(Fig. 5d). Persistence of dysplasia in myeloid cells confers
the title of AML post MDS to the disease [25, 32]. We
have previously shown in these mice an increase in react-
ive oxygen species (ROS) and the frequency of DNA
damage [35]. Contrary to the HR-MDS mice, but in line
with the leukemic features of these mice, the RAS:BCL2
complex, is here found at the mitochondria membrane, fa-
voring BCL2 pathways and increased survival of blast cells
[32]. The mitochondrial localization of the RAS:BCL2
complex was also noted in MDS patients with high blast
count and low levels of apoptosis [30]. As for the HR-MDS
Fig. 4 qRT-PCR validation of the GEP microarray data (blue) in Sca1+ cells purified from BM or spleen of another set of HR-MDS mice (two different
hues of orange), and CD34+ cells purified from MDS patients (green) compared to FBV/N or CD34 BM cells, respectively. Data expressed as fold
change of expression of several genes of three pathways shown (angpt1 (signal transduction); cox4i1 and ndufv2 (oxidative metabolism); sdc1
(DNA processing)). qRT-PCR fold changes shown here are represented as the average of three experiments
Table 3 Top regulated pathways in the list of downregulated genes in HR-MDS mice
Functional pathway KEGG database n Down P value Downregulated genesa
Cellular processes Inhibition of Apoptosis 5 1.2E-2 NAIP6, NAIP5, NLRC4, MAPK9, TNFAIP3
NAIP6; NAIP5: NLR family, apoptosis inhibitory protein 6; NLRC4: NLR family
CARD domain-containing protein 4; MAPK9: Mitogen activated kinase 9;
TNFAIP3: Tumor necrosis factor, alpha-induced protein 3
Environmental adaptation Circadian rhythm 3 1.4E-2 NR1D1, PER1, CLOCK
NR1D1: nuclear receptor subfamily 1, group D, member 1
PER1: period circadian clock 1
CLOCK: circadian locomotor output cycles kaput
Signal transduction Phosphatidylinositol signaling system 5 2.2E-2 PIK3C2A, PIK3C2B, PIP4K2A, PTEN, ITPR1
PIK3C2A: phosphatidylinositol-4-phosphate 3-kinase
PIP4K2A: phosphatidylinositol-5-phosphate 4-kinase, type II,
PTEN: phosphatase and tensin homolog
ITPR1: inositol 1,4,5-trisphosphate receptor type 1
Human diseasesType II diabetes mellitus 4 3.2E-2 IRS2, MAPK9, CACNA1E, SOCS4
IRS2: insulin receptor substrate 2; MAPK9: mitogen activated kinase 9
CACNA1E: calcium channel, voltage-dependent, R type, alpha 1E subunit
SOCS4: suppressor of cytokine signaling 4
Human diseasesPrimary immunodeficiency 3 9.3E-2 CD19, RFX5, CD40
CD19: antigen receptor of B lymphocytes; RFX5: regulatory factor X;
CD40: TNF receptor superfamily member 5
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Fig. 5 a Schematic representation of the AML post MDS mouse model. The characteristics of these models have previously been published [24-26;29];
b Decrease of the survival of AML post MDS mice compared to the survival of the funders, MRP8NRASD12 and MRP8hBCL-2; c Increased level of
Lin-Sca1+-cKit+ (LSK) cells in the BM; d Decreased level of apoptosis in the liver by whole body SPECT using 99Tc-Annexin (liver and spleen region
located above the kidneys); e Validation of microarray data: Decreased levels of MEK isoforms in the AML post MDS spleen cells compared to FVB/N
control mice by the nanofluidic proteomic analysis; f The disease can be transplanted in normal FVB/N irradiated syngeneic mice with either the Sca1+
cells of the spleen or BM of the AML post MDS mice resulting in 54 % blast infiltration in the BM blasts as in AML post MDS mice.[24-26;29]
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model, we have shown that injection of Sca1+ spleen cells
from AML post MDS mice transfers the disease in syngen-
eic mice (Fig. 5f) [32].
The GEP of these mice shows a total of 8026 dysregu-
lated genes compared to normal FVB/N mice (Fig. 6a, b),
as most (67 %, n = 5352) of these dysregulated genes
were common and with similar levels of expression be-
tween the AML post MDS mice and the founders (the
MRP8NRASD12 or the MRP8hBCL2 single transgenic
mice) (Additional file 1: Table S15). Gene Set Enrich-
ment Analysis (GSEA) was performed with the 8026
genes significantly dysregulated in AML post MDS mice
compared with normal FVB/N mice, highlighting enrich-
ment in cellular processes (cell cycle/DNA damage-repair),
cell metabolism (energy; lipid metabolism), and immune
system (Table 1 and Additional file 2: Figure S1B).
As for the HR-MDS model, to select differentially
expressed pathways implicated in the initiation or main-
tenance of the disease, we focused our study on Database
for Annotation, Visualization and Integrated Discovery
(DAVID) GEP analysis, on the 2620 dysregulated genes
that were unique to the AML post MDS mice (Additional
file 1: Table S16) and the 54 dysregulated genes that were
differentially expressed (i.e., upregulated in the AML post
MDS and downregulated in the founder mice and vice
versa) (Fig. 6d and Additional file 1: Table S17).
We first analyzed the 2620 genes unique to the AML
post MDS mice (Additional file 1: Table S16). DAVID
and KEGG functional annotation distributed the AML
post MDS dysregulated genes in functions similar to
those noted for the HR-MDS model, underscoring the
malignant background of both models (Fig. 6c). Like the
HR-MDS mouse, the majority of the genes were distributed
in pathways implicated in gene processing (DNA-RNA-
protein) (Additional file 1: Table S18), DNA-repair
(Additional file 1: Tables S19), cellular processes (cell
cycle (Additional file 1: Tables S20), survival/apoptosis
(Additional file 1: Table S21), signal transduction (Additional
file 1: Tables S22, S23), intracellular trafficking, membrane
transporters (Additional file 1: Table S24)), and genes of the
immune system (Additional file 1: Tables S25, S26). Other
pathways included energy and lipid metabolism (Tables 4
and 5; Additional file 1: Table S28), kinases (Additional
file 1: Table S23), Rho/Wnt pathway (Table 6 and Additional
file 1: Table S23C), and genes of splicing and epigenetic en-
zymes (Additional file 1: Tables S18, S27).
KEGG analysis identified 13 significantly dysregulated
pathways (Tables 4 and 5). The most upregulated pathway
concerned cell metabolism (Table 4). Indeed, in this
model, all the components of the oxidative phosphoryl-
ation pathway were upregulated (Fig. 3b) (complex I:
NADH dehydrogenase, complex II: fumarate reductase,
complex III: cytochrome bc1 complex, complex IV:
cytochrome c oxidase, and complex V: ATPase). Amongst
the other upregulated cell metabolism pathways were
those of nucleotide/pyrimidine metabolism. The upregula-
tion of these pathways are in line with the up regulation of
other cellular processes pathways such as: cell cycle,
DNA replication and repair (blm, rad18, rad51, rad54),
and multiple histone family genes, signaling molecules
and signal transduction (cytokine and cytokine receptors
including Epo, chemokines, TNFs, JAK-STAT signaling),
and the immune system with Toll receptor and inter-
feron pathways. All these pathways find their place in
the active leukemia features found in this mouse model
and have to some extent been reported either in MDS
or AML patients [20, 22, 29, 30, 32–35, 43]. Interest-
ingly, one study also highlighted the upregulation of
histone genes coding for histones 2 and 1 in MDS
patients [55].
Intriguingly, of the five most downregulated pathways
(Table 5), three concern signal transduction pathways.
The most significantly downregulated pathway was repre-
sented by numerous kinases of the MAPK (MEK) pathway
(MAP2K1, MAPK2P2 MAKA4P2, MAP3K7). These MAPK
genes also cluster in two functional annotation signal
transduction pathways (signal transduction and pathways
in cancer) with other enzymes or proteins acting down-
stream of environmental signaling such as bmp, Tgfβ, or
Wnt signaling. We confirmed the decreased expression of
one of these MAPK, MAP2K, at the protein level in an-
other set of AML post MDS mice cells by nanofluidic
proteomic immunoassay (Fig. 5e). The Wnt pathway
(found in the annotation “cancer pathways”) is the most
targeted pathway with 23 dysregulated genes (Tables 4
and 6). Fourteen of these genes were downregulated (such
as Dvl, Ppp3ca, Csnk1a1, Smad4, Rock1) while two genes
coding for inhibitors of Wnt signaling, Icat (Ctnnbip1)
and Disabled (Dab2) were upregulated (the latter by
nearly sevenfold). Other pathways pointed to a potential
dysfunction of interaction with the environment, such the
Rho signaling pathway (Additional file 1: Table S23C) and
the CD44 gene (Table 6). The downregulation of the Wnt
canonical pathway has already been underscored in sev-
eral studies in MDS patients [14, 19, 20, 22, 24, 56, 57].
However, our analysis also highlights that genes of the
noncanonical Wnt pathway (Rock1, Can, Ppp3ca, and
Rho/Rac GEF) are also altered. These combined altered
pathways underscore the importance of the regulation of
genes of the microenvironment in this disease [58]. Fi-
nally, in this model, genes of the class II PI3K family and
Pten were also downregulated as observed in the HR-
MDS model (Tables 2, 4, and 5).
As in the HR-MDS GEP study, we analyzed the 54
genes that were differentially expressed between the AML
post MDS model and its founders (i.e., upregulated in the
AML post MDS and downregulated in the founders or
vice versa) (Fig. 6d and Additional file 1: Table S15). These
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Fig. 6 a Venn diagrams of co-expressed and uniquely dysregulated genes compared to control FVB/N mice in the AML post MDS, MRP8NRASD12
and MRP8hBCL-2 transgenic mice; b Heat Map of GEP performed on the Sca1+ cells of AML post MDS mice (n = 3) compared to control FVB/N
mice (n = 3); c Distribution in % of the significantly dysregulated genes in the KEGG DAVID annotation pathways; d Analysis of the differentially
expressed (i.e., upregulated in the AML post MDS transgenic mice and downregulated in the founder mice and vice versa). Genes in regular font
are expressed at lower levels and genes in bold font are expressed in higher levels. Examples of microarray data are shown for each intersection
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genes predominated in the functional pathway gene pro-
cessing (DNA-RNA-protein) such as pmf1, btf3l4, bptf,
npm3, pol2rc, ncbp1, Ufm1, hnrnpf, and Hif1α. Several of
these genes are implicated in leukemogenesis such as
the npm genes (nmp1 and nmp3). HIF1α is a key part-
ner of glycolysis (Fig. 3b) [59] and a target gene of E2F3
[60]. Both HIF1α (Additional file 1: Table S17) and
E2F3 (Additional file 1: Table S16) genes are upregu-
lated in the AML post MDS. MDS patients have been
reported to express high levels of E2F3 and dhfr [61]
and Hif1α [62] underscoring the relevance of the mice
model. Genes of cellular processes such as survival/
Table 4 Top regulated pathways in the list of upregulated genes in AML post MDS mice
Functional pathway KEGG database n Up P Value Upregulated genesa
Cell metabolismOxidative
phosphorylation
18 1.0E-03 NDUFB5, NDUFB6, NDUFB8, ATP5B, COX4I1, NDUFC1, COX5A, LHPP, NDUFA10,
ATP5G3, PPA2, NDUFB2, ATP6V0C, ATP6V1A, UQCR11, NDUFV1, SDHC, COX6B2
NDUF family: NADH dehydrogenase (ubiquinone) Fe-S family
SDHC: succinate dehydrogenase complex, subunit C
LHPP: phospholysine phosphohistidine inorganic pyrophosphate phosphatase
Nucleotide metabolism Pyrimidine
metabolism
14 2.9E-03 POLR2G, NUDT2, DTYMK, POLE, AK3, POLA1, POLR2C, NME4, TYMP, POLE3, NME1,
POLD1, ENTPD1, DUT
NUDT2: nucleoside diphosphate, AK3: adenylate kinase
TYMP: thymidine phosphorylase, NME: nucleoside diphosphate kinase
POLE, POLR2C, POLE3, PLD1: polymerases, DUT: deoxyuridine triphosphate
Immune systemToll-like receptor
signaling
14 3.8E-03 MAP2K3, MAP2K4, TLR4, FADD, CXCL11, TLR7, CCL4, TLR8, CD80, IFNA7, MAPK13,
IFNA5, TICAM2, PIK3R2
MAP2K3, MAP2K4: MEK proteins, TICAM2: TIR domain-containing adapter molecule 2
PIK3R2: Phosphatidylinositol 3-kinase regulatory subunit beta
Cellular processesCell cycle 16 5.8E-03 CDC6, E2F3, CCNH, SKP2, YWHAB, ESPL1, CDC20, CHEK1, CHEK2, CDC25C, MCM4,
2CDK2, CCNE2, CDC45, MAD2L1, CDKN2C
CCNH: cyclin H; SKP2: S-phase kinase-associated protein 2; YWHAB: 14-3-3 protein beta/alpha
ESPL1:separin, CCNE2: cyclin E2, MAD2L1: MAD2 mitotic arrest deficient-like 1
CDKN2: cyclin-dependent kinase inhibitor 2A (p16)
Signaling molecules Cytokine-
cytokine receptor
25 5.9E-03 IL1R1, ACVRL1, PDGFB, IL13, CXCL11, CCL4, TNFRSF4, IL10, IL12RB2, CCL22, IFNA7,
IFNA5, TNFRSF18, IFNGR1, EPO, IL4, IL23R, IL21, CCL17, TNFRSF9, INHBA, CCR8,
TNFSF11, CXCL13, CCR2
IL1R1, IL12RB, I L23R,IL21: interleukines/interleukine receptor
CCL4, CCL22, CCL17, CXCL11, CXCL13 CCR2, CCR8: chemokine
TNFRSF4, TNFRSF18, TNFRSF9, TNFSF11. Tumor necrosis receptor
IFNA7, IFNA5, INFGR1, INHBA: interferon signaling
EPO: erythropoietin
Signal transductionJAK-STAT
signaling pathway
15 5.0E-02 IL4, IL23R, SOCS2, IL13, IL21, IL10, IL12RB2, SPRY1, IFNA7, IFNA5, SPRED2, IFNGR1,
IL13RA2, EPO, PIK3R2
IL4, IL23R, IL13, IL21, IL10, IL12RB2, IL13RA2: interleukines/interleukine receptor
IFNA7, IFNA5, IFNGR1: interferon signaling
EPO: erythropoietin
PIK3R2: phosphoinositide-3-kinase, regulatory subunit 2
Genetic information processing.
Replication and repair
5 6.4E-02 BLM, RAD51L1, POLD1, RAD54B, RAD51
BLM: bloom syndrome protein, POLD1: polymerase delta
RAD51L1, RAD54B, RAD51: recombinases family
Genetic information processing 11 6.8E-02 HIST1H2AC, C4A, H2AFV, CD80, HIST2H2BE, HIST2H2AC, HIST1H2BH, HIST1H2AI,
SNRPB, H2AFY, FCGR1, IL10
HIST1H2AC,H2AFV,HIST2H2BE,HIST2H2AC,HIST1H2BH, HIST1H2AI, H2AFY: histone proteins
C4A: complement factor 4; CD80, costimulatory factor, SNRPB: small nuclear
ribonucleoprotein-associated proteins B, FCGR1: IgG Fc receptor
aGene card nomenclature
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apoptosis, cell cycle, and DNA repair were also differen-
tially expressed. Genes of cell metabolism were also identi-
fied such as genes coding for succinate-CoaA ligase,
cytochrome c oxidase (Coxa5, Cox6), Coq4, or dihydrofo-
late reductase (dhfr). Two genes (cysc and hnrnpf) were
dysregulated between the AML post MDS mice and both
founder. The Hnrnpf gene (heterogeneous nuclear ribonu-
cleoprotein F) is involved in the regulation of alternative
splicing [63] and has been found altered in myeloid malig-
nancies [63] while the cysc gene codes for cytochrome C
in the electron respiratory chain and is also a major
mitochondrial initiator of the apoptosis intrinsic pathway
(Fig. 3b). Finally, other dysregulated genes involved mem-
brane transporter genes (such as iron (Slc40a1/ferroportin),
calcium (Orai2), H+/Cl- (clnc5), small RNAs (Sidt1),
ankyrine (ankrd55) or membrane receptor genes (vaso-
pressine (Vipr1), scavenger (CD163), mannose phos-
phate (M6pr-ps), chemokine (ccr3), and IL12 (IL12tb2).
Of note, the role of the iron transporter was reported
in MDS [64].
Validation of GEP
The GEP microarray data was validated on a different
set of HR-MDS mice produced a year after the mRNA
extraction for the GEP analysis on both BM and spleen
Sca1+ purified cells. A similar dysregulation of gene ex-
pression was noted on three selected pathways, angpt1
(signal transduction), cox4i1 and ndufv2 (oxidative
metabolism), and sdc1 (DNA processing). For all these
genes, there was a concordance between (a) the array ana-
lysis and the RT-PCR study and (b) a concordance be-
tween the spleen and bone marrow gene expression
validating the study performed on spleen cells (Fig. 4). We
also confirmed the decreased expression of one of these
MAPK, MAP2K, at the protein level in another set of
AML post MDS mice cells by nanofluidic proteomic im-
munoassay (Fig. 5e).
The relevance of the GEP results was also validated in
CD34+ BM cells of MDS patients (n = 3) on the same
gene panel. For these pathways (signal transduction, oxida-
tive metabolism, and DNA processing), the dysregulation
was the same in the BM of HR-MDS mice and MDS pa-
tient CD34+ BM cells when compared to normal FVB/N
control cells and normal CD34 BM cells (Fig. 4). This is
the only discrepancy we noted when comparing the HR-
MDS mice GEP data with gene expression data in MDS
patient samples (whether from data of the literature or
validation analysis performed in this study). However,
the complete disruption noted in the MDS patient sam-
ples is in line with that reported in patients with solid
tumors [65, 66] and strengthens their potential relevance
to human MDS though how these pathways impact on
the disease still needs to be elucidated as in solid tumors.
Thus, the GEP analysis of these mice, at the gene ex-
pression level, validates them as unique models of human
MDS, at two different stages of the human MDS disease,
Table 5 Top regulated pathways in the list of downregulated genes in AML post MDS mice
Functional pathway KEGG database n Down P value Downregulated genesa
Cellular processes Inhibition of Apoptosis 5 1.2E-2 NAIP6, NAIP5, NLRC4, MAPK9, TNFAIP3
NAIP6; NAIP5: NLR family, apoptosis inhibitory protein 6; NLRC4: NLR family CARD
domain-containing protein 4; MAPK9: mitogen activated kinase 9; TNFAIP3: tumor
necrosis factor, alpha-induced protein 3
Environmental adaptation Circadian rhythm 3 1.4E-2 NR1D1, PER1, CLOCK
NR1D1: nuclear receptor subfamily 1, group D, member 1
PER1: period circadian clock 1
CLOCK: circadian locomotor output cycles kaput
Signal transduction Phosphatidylinositol
signaling system
5 2.2E-2 PIK3C2A, PIK3C2B, PIP4K2A, PTEN, ITPR1
PIK3C2A: phosphatidylinositol-4-phosphate 3-kinase
PIP4K2A: phosphatidylinositol-5-phosphate 4-kinase, type II,
PTEN: phosphatase and tensin homolog
ITPR1: Inositol 1,4,5-trisphosphate receptor type 1
Human diseasesType II diabetes mellitus 4 3.2E-2 IRS2, MAPK9, CACNA1E, SOCS4
IRS2: insulin receptor substrate 2; MAPK9: mitogen activated kinase 9
CACNA1E: calcium channel, voltage-dependent, R type, alpha 1E subunit
SOCS4: suppressor of cytokine signaling 4
Human diseasesPrimary immunodeficiency 3 9.3E-2 CD19, RFX5, CD40
CD19: antigen receptor of B lymphocytes; RFX5: regulatory factor X ;
CD40: TNF receptor superfamily member 5
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high risk (HR-MDS), and at transformation (AML post
MDS). Though published MDS mice models have pro-
vided insights to initiating mechanisms such as splicing
abnormalities, chromosomal deletions, or abnormalities of
the microenvironment [25, 67], most are characterized by
myeloid proliferation, whether chronic or acute, with little
reported analysis of apoptosis, and very few have achieved
a translational benefit.
The majority of the identified pathways in the HR-MDS
and AML post MDS mice identified by this GEP analysis
are similar to those reported in similar annotation studies
performed in MDS patients, when all analyses are com-
bined [11–14, 16, 18–22, 24, 43, 45, 56–58, 64, 68–77].
Most of the dysregulated pathways were expected in a
malignant context, such as pathways of gene processing,
intracellular trafficking, cell cycle, DNA damage-repair,
signal transduction, the immune system, and oxidative
metabolism (Fig. 7a), and confirmed by GSEA analysis per-
formed on all genes dysregulated in HR-MDS (Additional
file 1: Table S29, Additional file 2: Figure S1A) or AML
post MDS (Additional file 1: Table S30, Additional file 2:
Figure S1B) vs FVB/N mice. The latter three annotation
pathways are more frequently dysregulated in the AML
post MDS mice. A more focused analysis on pathways now
known to be implicated in MDS and AML [3, 18] also
identified dysregulation of genes coding for epigenetic pro-
teins (Additional file 1: Table S13 and S27), enzymes in-
volved in methylation and acetylation processes
(Additional file 1: Tables S4, S18 and Additional file 3:
Figure S2D) as well as genes implicated in splicing and
translation in both diseases (Additional file 1: Tables S4,
S16, S18), confirming the importance of altered epigenetic,
splicing, or ribosomal pathways in MDS diseases whether
they are induced by mutations or altered gene expression.
Thus, both mice models may be useful to further analyze
and target these known pathways.
The GEP and annotation analysis equally identified
novel dysregulated pathways, most of which have been
identified in the solid tumor field but not as yet in AML
or MDS. These pathways, detailed above, concern lipid
and ether metabolism, the proteasome, MAPKinases, and
more specifically, the noncanonical Wnt (Fig. 7b). The
dysregulation of these pathways was confirmed by the
differential gene expression (or nanofluidic proteomic
immunoassay) seen in the BM and spleen cells of a dif-
ferent set of MDS mice and in the BM CD34+ cells of
Table 6 Genes implicated in WNT signaling differentially dysregulated in the AML post MDS transgenic mice compared to control
FVB/N mice
Gene symbol Gene name Regulation Fold change P value
Mesdc2 Mesoderm development candidate 2 Up 1.98 1.92E-02
Csnk2b Casein kinase 2, beta polypeptide Up 1.88 1.76E-02
Fzd7 Frizzled homolog 7 Up 1.75 2.74E-03
Ctnnb1 Catenin (cadherin associated protein), beta 1 Up 1.74 4.24E-04
Bambi BMP and activin membrane-bound inhibitor, homolog (Xenopus laevis) Up 1.73 1.56E-02
Dab2 Disabled homolog 2 Up 6.67 2.12E-02
Cd44 CD44 antigen Up 1.68 5.96E-03
Wdr61 WD repeat domain 61 Up 1.64 7.57E-04
Sdc1 Syndecan 1 Up 3.11 5.94E-03
Hhex Hematopoietically expressed homeobox Down 1.98 2.46E-02
Macf1 Microtubule-actin crosslinking factor 1 Down 1.94 8.80E-03
Mark2 MAP/microtubule affinity-regulating kinase 2 Down 1.94 2.41E-02
Tnik TRAF2 and NCK interacting kinase Down 1.91 3.10E-03
Tle1 Transducin-like enhancer of split 1, homolog of Drosophila E(spl) Down 1.88 1.51E-02
Dvl2 Dishevelled 2, dsh homolog (Drosophila) Down 1.67 7.34E-03
Csnk1a1 Casein kinase 1, alpha 1 Down 1.65 1.27E-02
Rock1 Rho-associated coiled-coil containing protein kinase 1 Down 1.61 7.04E-03
Map3k7 Mitogen-activated protein kinase kinase kinase 7 Down 1.58 9.96E-04
Smad4 MAD homolog 4 Down 1.54 6.36E-03
Dapk3 Death-associated protein kinase 3 Down 1.52 1.06E-02
Tbl1xr1 Transducin (beta)-like 1X-linked receptor 1 Down 1.52 8.39E-04
Ppp3ca Protein phosphatase 3, catalytic subunit, alpha isoform Down 1.50 9.70E-03
Ppap2b Phosphatidic acid phosphatase type 2B Down 2.10 2.74E-02
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MDS patients when compared to their normal counter-
parts (Figs. 2e, 4). How these dysregulations occur and
impact on the initiation or maintenance of MDS and in
the networks of the other dysregulated pathways will
require further studies.
Conclusions
In conclusion, this study confirms that the HR-MDS and
AML post MDS mice mimic two stages of the human
MDS disease not only in their clinical and biological
level but also in their gene expression level. This study
further highlights novel less well studied pathways such
as energy and lipid metabolism and noncanonical Wnt
signaling which may concur with epigenetics and DNA
damage to the genomic instability of these diseases. These
MDS models should help unravel the underlying networks
at the origin of these dysregulation and provide further
biomarkers and targets for MDS disease.
Fig. 7 a Frequency in percent of the most significant pathways dysregulated (up- or downregulated) in the two MDS mice models; b Schematic
summary of the dysregulated pathways noted in the two MDS mice models. Upregulated pathways (gray boxes), downregulated pathways (white boxes)
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Methods
Transgenic mice
The MRP8[NRASD12/hBCL-2] (AML post MDS) and
MRP8NRASD12/tethBCL-2 (HR-MDS) transgenic mice were
generated from crosses of MRP8hBCL-2 or MMTVLTRtTA/
TetohBCL-2 (tethBCL-2) with MRP8NRASD12 hemizygote
mice in FVB/N, as previously described [33, 34]. For geno-
typing, DNA was extracted from the tails of 3-week-old
mice using the KAPA Express Extraction Kit using
manufacturer instructions. The PCR reaction was then
performed with REDTaq® ReadyMixTM PCR Reaction
Mix with MgCl2. Mice were classified according to the
Bethesda classification [78] as HR-MDS or AML post
MDS-like by cytological and pathology criteria. Mice
were maintained in the barrier facilities of the Institut
Universitaire d’Hématologie. Procedures involving ani-
mals and their care conformed with institutional guide-
lines that comply with national and international laws
and policies and were authorized by the local ethical
committee. Mice were sacrificed when they were mori-
bund or upon veterinary advise. Committee on the Ethics
of Animal Experiments Paris-Nord: C2EA-121 approved
this project no. 2014IUH006
Cell and tissue preparation, flow cytometry
The bone marrow (BM) was obtained by flushing long
bones with Hank’s balanced salts solution followed by
filtering through a nylon mesh. BM smears were pre-
pared according to standard hematological techniques.
BM smears were stained and examined by a cytologist
(MEN) of Hôpital Saint-Louis. Percentage blasts were
determined from the BM smears by counting 100–200
cells. Spleen cells from AML post MDS mice (day 36
post birth) and HR-MDS mice (day 80 post birth) were
obtained by soft dilaceration of the spleen with the pis-
ton of a 5-ml syringe in a petri dish. Cells were washed
in PBS, filtered through a 40-μm nylon mesh and then
density centrifugation was conducted using Lymphoprep
(Eurobio, France) to isolate mononuclear cells. Spleen or
BM cells were labeled with anti-Sca1+ antibodies coupled
with microbeads from Miltenyi and then sorted using an
AutoMacs separator (Miltenyi Biotec Bergisch Gladbach,
Germany). 5.106 to 107 Sca1+ sorted cells were used to
extract total RNA using TRIzol (Invitrogen, CA, USA).
Quantification and quality of the RNAs were assessed
using a Nanodrop (Thermoscientific, USA).
Secondary transplantation of bone marrow and spleen cells
Bone marrow cells, isolated from long bones, and spleen
cells were harvested from 6- to 10-week-old AML post
MDS mice as described above, pooled and divided (107
nucleated cell aliquots per recipient) for i.v. injections
into 12 irradiated FVB/N mice. Six- to 8-week-old FVB/
N mice were prepared for transplantation by cesium
irradiation totaling 10 Gy, divided into two doses 3 to
4 h apart. Successful transfer of the transgene-positive
cells was confirmed by PCR. Spleen cells (105, 106, or
107) from HR-MDS mice were injected i.v. in tail veins
of immunocompromised RAG1-deficient mice, which
are B cell and T cell deficient. [79]
Nanofluidic proteomic immunoassay (NanoPro assay)
Splenocyte cells (106) isolated from transgenic mice were
lysed in radio immunoprecipitation assay buffer and sub-
jected to a nanofluidic proteomic immunoassay (NIA) run
on the NanoPro1000, as we have previously described [80]
(ProteinSimple, Santa Clara, CA) mixing 0.1 mg/mL of
lysate in a final volume of 15 μL loaded in a 384-well plate
with five to eight gradient ampholyte mix. Antibodies
were diluted in ProteinSimple antibody diluent: mitogen-
activated protein kinase (MEK)1 (Upstate 07-641;
Millipore, Billerica, MA) 1:100. Samples were run in
triplicate.
99Tc-Annexin scintigraphy
Single-Photon Emission Computed Tomography (SPECT)
was performed under pentobarbital anesthesia (4 mg/
100 g body weight; Ceva Santé Animale, Libourne, France)
in mice, after intravenous injection of 99Tc-Annexin. Images
were acquired 10 min after injected dose of 99Tc-Annexin.
Planar images were obtained 0 to 45 min (dynamic acquisi-
tion: 15 images, image duration: 60 s, static acquisitions
of 10 min duration) after 99Tc-Annexin injection. In
addition, mice which had previously undergone planar
imaging underwent abdominal X/tomoscintigraphy ac-
quisition: mod-list tomographic acquisition was performed
during continuous rotation of the animal placed between
two parallel collimators (360° rotation per minute, acquisi-
tion duration: 60 min from 1 h to 2 h after 99Tc-Annexin
injection). All acquisitions were performed using a ded-
icated small animal IMAGER-S/CT system (Biospace
Mesures, Paris, France) equipped with parallel low-energy
high-resolution collimators (matrix 128 × 128, 15 % energy
window centered on 140 KeV). 99Tc-Annexin uptake in
hepato-splenic area was visually assessed.
Affymetrix exon array hybridization
One microgram of total RNA extracted from Sca1+ spleen
cells from the AML post MDS mice, HR-MDS mice, single-
transgenic mice necessary to produce these AML post MDS
and HR-MDS mice, (MRP8NRASD12, MRP8hBCL-2, tethBCL-2)
(called founder mice), and FBV/N control mice (n=3 each)
was labeled with Affymetrix reagents and hybridized to
Affymetrix-GeneChip Mouse Exon 1.0 ST arrays. Affy-
metrix Expression Console Software was used to perform
quality assessment.
For each of the 18 arrays (MRP8NRASD12/tethBCL-2,
MRP8[NRASD12/hBCL-2], MRP8NRASD12, MRP8hBCL-2,
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tethBCL-2, and the control FVB/N mice), 100 ng of total
RNA was first mixed with bacterial transcripts and the
mixture was reverse transcribed into complementary DNA
(cDNA). After synthesis of double-stranded cDNA, an in
vitro transcription reaction was conducted overnight.
Resulting amplified cRNA was reverse transcribed into
sense DNA incorporating dUTP. This single-stranded
DNA was treated with a combination of uracil DNA glyco-
sylase and apurinic/apyrimidinic endonuclease 1. DNA
fragments were biotin-labeled by terminal deoxynucleotidyl
transferase. Targets were finally prepared according to Affy-
metrix recommendations for hybridization of exon arrays.
Microarrays were hybridized, washed, and scanned using
Affymetrix instruments. Total RNAs RIN values were
between 8.3 and 9. Raw data are controlled with Ex-
pression console (Affymetrix).
Microarray data and statistical analysis
Affymetrix exon array data analyses were performed
using EASANA based on FAST DB annotations [81]
(GenoSplice technology; http://www.genosplice.com/).
Unpaired statistical analyses were performed using Stu-
dent’s paired t test as previously described [82]. Affymetrix
Expression Console Software was used to perform quality
assessment. All array present a “pos_vs_neg_auc” value
greater or equal than 0.82; All arrays present a “all_probe-
set_rle_mean” value lesser or equal than 0.35; All arrays
present a “%” value greater or equal than 65 % and less
than 6 % of difference between arrays from the same ex-
perimental condition.
Regarding the expression status/background noise
analysis, only probes with a DABG P value ≤0.05 in at
least half of the arrays from a given experimental condi-
tion were considered for further statistical analysis.
We kept a cutoff of P value ≤ 0.05 of increase or de-
crease of expression compared to normal samples for
the analysis [83], Gene Set Enrichment Analysis (GSEA),
and gene ontology using the Database for Annotation,
Visualization and Integrated Discovery (DAVID) (http://
https://david.abcc.ncifcrf.gov) were performed [84–87].
Though our analysis is focused on the unique genes dys-
regulated in the HR-MDS and the AML post MDS trans-
genic mice and sets of genes differentially expressed in
HR-MDS or AML post MDS and founders, the data from
all mice was analyzed as of potential relevance to the initi-
ation of the disease (Additional file 1: Tables S1-28). This
resulted in a selection of 2674 genes unique for AML post
MDS and 715 for HR-MDS that were used for functional
analysis. Microarray data from this study were included in
the NCBI Gene Expression Omnibus no. GSE72934.
HR-patient samples
BM aspirates from MDS patients were obtained in ac-
cordance with the Declaration of Helsinki. Participants
provide their written informed consent to participate in
Cancer research. The study presented here is part of a
study approved by “Comité d’Evaluation de l’Ethique
des Projets de Recherche Biomédicale” (CEERB) Paris
Nord—IRB00006477—on 17 June 2013 (opinion number
13-027).
Patients had been diagnosed according to the World
Health Organization (WHO) 2008 classification [88, 89].
CD34+ enriched cells were obtained by using anti-CD34+
antibodies coupled with microbeads from Miltenyi and
then sorted using an AutoMacs separator (Miltenyi Biotec
Bergisch Gladbach, Germany). CD34+ sorted cells were
used to extract total RNA using TRIzol (Invitrogen, CA,
USA).
Real-time RT-PCR
Total RNA (1 μg) was reverse transcribed with SuperScript
III reverse transcriptase (Invitrogen) using 100 ng of
Random Hexamers. Quantitative real-time RT-PCR was
performed in a test set of HR-MDS mice (n = 3) Sca1+
enriched BM and spleen cells and MDS patients (n = 3)
CD34+ enriched BM using Power SYBR® Green (Applied
Biosystems) and 7500 Fast Real-Time PCR System, Applied
Biosystems. Primer sequences are detailed in Additional
file 1: Table S31.
Additional files
Additional file 1: Lists of regulated genes in HR-MDS and AML post
MDS relative to FVB/N (Tables S1 to S31). (XLSX 1839 kb)
Additional file 2: Figure S1. GSEA analysis, (A) Endplot of significantly
dysregulated pathways in HR-MDS vs FVB/N, (B) Endplot of significantly
dysregulated pathways in AML post MDS vs FVB/N (ZIP 5853 kb)
Additional file 3: Figure S2. In a preliminary work, mRAS-BCL2 (referred
in this study as MRP8[NRASD12/ hBCL-2], AML post MDS mice) transgenic
mice Sca1+ spleen cells genes were analyzed on Affimetrix 430A mouse
arrays. Compared to normal FVB/N Sca1+ spleen cells, (A) DAVID analysis,
(B) Principal component analysis (PCA), and hierarchical clustering, were
performed with R software (http://www.R-project.org) and Partek Genomics
Suite (http://www.partek.com). Each sphere represents a single GEP from a
given transgenic mouse: mRas (referred in this study as MRP8NRASD12
transgenic mice), mBCL2 transgenic mice (referred in this study as
MRP8hBCL-2 transgenic mice), mRAS-BCL2 transgenic mice (referred in
this study as MRP8[NRASD12/ hBCL-2] or AML post MDS transgenic mice),
(C) Gene spring single gene analysis identified significant up-regulation of
ADA, KRTCAP2, SSR4, CKAP4 and ATPG3 genes in mRAS-BCL2 transgenic
mice (referred in this study as MRP8[NRASD12/ hBCL-2] or AML post MDS
transgenic mice). (D). In this study; ADA and KRTCAP2 were up dysregulated
in MRP8hBCL2 (mBCL2), AML post MDS (mRAS-BCL2) and HR-MDS
transgenic mice Sca1+ spleen cells; SSR4 in AML post MDS (mRAS-BCL2) and
HR-MDS transgenic mice Sca1+ spleen cells and; CKAP4 and ATPG3 in AML
post MDS (mRAS-BCL2) transgenic mice Sca1+ spleen cells. (TIF 30355 kb)
Competing interests
P. de la Grange is a salaried employee of Genosplice. The remaining authors
have no relevant conflict of interests.
Authors’ contributions
LG, SB, MS, PG, and CLP carried out all the experiments; PdlG carried out the
Affymetrix exon array and analysis; NO carried out the secondary transplant;
VV carried out the preparation of human CD34+ cells; LSM performed SPECT;
Guerenne et al. Journal of Hematology & Oncology  (2016) 9:5 Page 17 of 20
MEN performed cytology and validated clinical features; KM performed the
PCA analysis; GJM supervised his graduate student MS; MP was responsible
for the animal facilities; PF was responsible for the recruitment of patients;
FG, RAP, CC, and PK designed the experiments, analyzed the data, and wrote
the manuscript. All authors read and approved the final manuscript.
Acknowledgements
This work was supported by grants from INSERM, Université Paris Diderot,
Fondation de France, Association pour la Recherche Contre sur le Cancer,
Association Laurette Fugain, Ligue Contre le Cancer. FP7 Marie Curie N° N°
264361
Author details
1Université Paris-Diderot, Sorbonne Paris Cité, Institut Universitaire
d’Hématologie, Unité Mixte de Recherche (UMR-S) 1131, Paris, France.
2Institut National de la Santé et de la Recherche Médicale (INSERM) Unité (U)
1131, Paris, France. 3Department of Haematological Medicine, King’s College
London and Kings College Hospital, London, UK. 4GenoSplice technology,
iPEPS-ICM, Hôpital de la Pitié Salpêtrière, Paris, France. 5Haematology
Department, Cardiff University School of Medicine, Cardiff, UK. 6Assistance
Publique-Hôpitaux de Paris (AP-HP), Unité de Thérapie Cellulaire, Hôpital
Saint Louis, Paris, France. 7Centre for Cancer Research and Cell Biology,
Queen’s University Belfast, Belfast, UK. 8Université Paris-Diderot, Sorbonne
Paris Cité, Institut Universitaire d’Hématologie Hôpital Saint Louis, Paris,
France. 9Assistance Publique-Hôpitaux de Paris (AP-HP), Service de Médecine
Nucléaire, Hôpital Lariboisière, Paris, France. 10Assistance Publique-Hôpitaux
de Paris (AP-HP), Laboratoire d’Hématologie, Hôpital Saint Louis, Paris, France.
11Université Paris-Diderot, Sorbonne Paris Cité, Département
d’Expérimentation Animale, Institut Universitaire d’Hématologie, Paris, France.
Received: 24 October 2015 Accepted: 19 January 2016
References
1. Mughal TI, Cross NC, Padron E, Tiu RV, Savona M, Malcovati L, et al. An
International MDS/MPN Working Group’s perspective and recommendations
on molecular pathogenesis, diagnosis and clinical characterization of
myelodysplastic/myeloproliferative neoplasms. Haematologica.
2015;100(9):1117–30.
2. Fenaux P, Ades L. How we treat lower-risk myelodysplastic syndromes.
Blood. 2013;121(21):4280–6.
3. Cazzola M, Della Porta MG, Malcovati L. The genetic basis of myelodysplasia
and its clinical relevance. Blood. 2013;122(25):4021–34.
4. Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, et al.
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.
Leukemia. 2014;28(2):241–7.
5. Hajkova H, Fritz MH, Haskovec C, Schwarz J, Salek C, Markova J, et al.
CBFB-MYH11 hypomethylation signature and PBX3 differential methylation
revealed by targeted bisulfite sequencing in patients with acute myeloid
leukemia. J Hematol Oncol. 2014;7:66.
6. Malcovati L, Papaemmanuil E, Ambaglio I, Elena C, Galli A, Della Porta MG,
et al. Driver somatic mutations identify distinct disease entities within
myeloid neoplasms with myelodysplasia. Blood. 2014;124(9):1513–21.
7. Ok CY, Patel KP, Garcia-Manero G, Routbort MJ, Peng J, Tang G, et al. TP53
mutation characteristics in therapy-related myelodysplastic syndromes and
acute myeloid leukemia is similar to de novo diseases. J Hematol Oncol.
2015;8:45.
8. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van LP, et al.
Clinical and biological implications of driver mutations in myelodysplastic
syndromes. Blood. 2013;122(22):3616–27.
9. Skvarova KK, Fiser K, Mejstrikova E, Rejlova K, Zaliova M, Fornerod M, et al.
Homeobox gene expression in acute myeloid leukemia is linked to typical
underlying molecular aberrations. J Hematol Oncol. 2014;7:94.
10. Visconte V, Tabarroki A, Zhang L, Parker Y, Hasrouni E, Mahfouz R, et al.
Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features
of low risk Myelodysplastic syndromes with ring sideroblasts. J Hematol
Oncol. 2014;7:89.
11. Wang H, Wen J, Chang CC, Zhou X. Discovering transcription and splicing
networks in myelodysplastic syndromes. PLoS One. 2013;8(11):e79118.
12. Chen G, Zeng W, Miyazato A, Billings E, Maciejewski JP, Kajigaya S, et al.
Distinctive gene expression profiles of CD34 cells from patients with
myelodysplastic syndrome characterized by specific chromosomal
abnormalities. Blood. 2004;104(13):4210–8.
13. Del Rey M, O’Hagan K, Dellett M, Aibar S, Colyer HA, Alonso ME, et al.
Genome-wide profiling of methylation identifies novel targets with aberrant
hypermethylation and reduced expression in low-risk myelodysplastic
syndromes. Leukemia. 2013;27(3):610–8.
14. Dellett M, O’Hagan KA, Colyer HA, Mills KI. Identification of gene networks
associated with acute myeloid leukemia by comparative molecular
methylation and expression profiling. Biomark Cancer. 2010;2:43–55.
15. Dolatshad H, Pellagatti A, Fernandez-Mercado M, Yip BH, Malcovati L,
Attwood M, et al. Disruption of SF3B1 results in deregulated expression and
splicing of key genes and pathways in myelodysplastic syndrome
hematopoietic stem and progenitor cells. Leukemia. 2015;29(5):1092–103.
16. Galili N, Raza A. Clinical implications of gene expression profiling in
myelodysplastic syndromes: recognition of ribosomal and translational gene
dysregulation and development of predictive assays. Best Pract Res Clin
Haematol. 2009;22(2):223–37.
17. Gerstung M, Pellagatti A, Malcovati L, Giagounidis A, Porta MG, Jadersten M,
et al. Combining gene mutation with gene expression data improves outcome
prediction in myelodysplastic syndromes. Nat Commun. 2015;6:5901.
18. Hofmann WK, de Vos S, Komor M, Hoelzer D, Wachsman W, Koeffler HP.
Characterization of gene expression of CD34+ cells from normal and
myelodysplastic bone marrow. Blood. 2002;100(10):3553–60.
19. Li L, Li M, Sun C, Francisco L, Chakraborty S, Sabado M, et al. Altered
hematopoietic cell gene expression precedes development of therapy-related
myelodysplasia/acute myeloid leukemia and identifies patients at risk. Cancer
Cell. 2011;20(5):591–605.
20. Pellagatti A, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta MG,
et al. Deregulated gene expression pathways in myelodysplastic syndrome
hematopoietic stem cells. Leukemia. 2010;24(4):756–64.
21. Pellagatti A, Benner A, Mills KI, Cazzola M, Giagounidis A, Perry J, et al.
Identification of gene expression-based prognostic markers in the
hematopoietic stem cells of patients with myelodysplastic syndromes. J Clin
Oncol. 2013;31(28):3557–64.
22. Sridhar K, Ross DT, Tibshirani R, Butte AJ, Greenberg PL. Relationship of
differential gene expression profiles in CD34+ myelodysplastic syndrome
marrow cells to disease subtype and progression. Blood. 2009;114(23):4847–58.
23. Taskesen E, Havermans M, van Lom K, Sanders MA, van Norden Y, Bindels E,
et al. Two splice-factor mutant leukemia subgroups uncovered at the
boundaries of MDS and AML using combined gene expression and DNA-
methylation profiling. Blood. 2014;123(21):3327–35.
24. Theilgaard-Monch K, Boultwood J, Ferrari S, Giannopoulos K, Hernandez-Rivas JM,
Kohlmann A, et al. Gene expression profiling in MDS and AML: potential and
future avenues. Leukemia. 2011;25(6):909–20.
25. Beurlet S, Chomienne C, Padua RA. Engineering mouse models with
myelodysplastic syndrome human candidate genes; how relevant are they?
Haematologica. 2013;98(1):10–22.
26. Chau D, Ng K, Chan TS, Cheng YY, Fong B, Tam S, et al. Azacytidine
sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating
the arsenic transporter aquaglyceroporin 9. J Hematol Oncol. 2015;8:46.
27. Zhou T, Kinney MC, Scott LM, Zinkel SS, Rebel VI. Revisiting the case for
genetically engineered mouse models in human myelodysplastic syndrome
research. Blood. 2015;126(9):1057–68.
28. Raaijmakers MH, Mukherjee S, Guo S, Zhang S, Kobayashi T, Schoonmaker JA,
et al. Bone progenitor dysfunction induces myelodysplasia and secondary
leukaemia. Nature. 2010;464(7290):852–7.
29. Beurlet S, Omidvar N, Gorombei P, Krief P, Le Pogam C, Setterblad N, et al.
BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse
model of AML by targeting primitive LSK and progenitor cells. Blood.
2013;122(16):2864–76.
30. Le Pogam C, Krief P, Beurlet S, Soulie A, Balitrand N, Cassinat B, et al.
Localization of the NRAS:BCL-2 complex determines anti-apoptotic features
associated with progressive disease in myelodysplastic syndromes. Leuk Res.
2013;37(3):312–9.
31. Le Pogam C, Patel S, Gorombei P, Guerenne L, Krief P, Omidvar N, et
al. DNA-mediated adjuvant immunotherapy extends survival in two
different mouse models of myeloid malignancies. Oncotarget. 2015;
6(32):32494–508.
32. Omidvar N, Kogan S, Beurlet S, Le Pogam C, Janin A, West R, et al. BCL-2
and mutant NRAS interact physically and functionally in a mouse model of
progressive myelodysplasia. Cancer Res. 2007;67(24):11657–67.
Guerenne et al. Journal of Hematology & Oncology  (2016) 9:5 Page 18 of 20
33. Padua RA, Guinn BA, Al-Sabah AI, Smith M, Taylor C, Pettersson T, et al. RAS,
FMS and p53 mutations and poor clinical outcome in myelodysplasias: a
10-year follow-up. Leukemia. 1998;12(6):887–92.
34. Parker JE, Mufti GJ, Rasool F, Mijovic A, Devereux S, Pagliuca A. The role of
apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic
syndromes and acute myeloid leukemia secondary to MDS. Blood.
2000;96(12):3932–8.
35. Rassool FV, Gaymes TJ, Omidvar N, Brady N, Beurlet S, Pla M, et al. Reactive
oxygen species, DNA damage, and error-prone repair: a model for
genomic instability with progression in myeloid leukemia? Cancer Res.
2007;67(18):8762–71.
36. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and
non-oncogene addiction. Cell. 2009;136(5):823–37.
37. Terpos E, Verrou E, Banti A, Kaloutsi V, Lazaridou A, Zervas K. Bortezomib is an
effective agent for MDS/MPD syndrome with 5q- anomaly and thrombocytosis.
Leuk Res. 2007;31(4):559–62.
38. Yue Y, Wang Y, He Y, Yang S, Chen Z, Wang Y, et al. Reversal of bortezomib
resistance in myelodysplastic syndrome cells by MAPK inhibitors. PLoS One.
2014;9(3):e90992.
39. Benjamin DI, Cozzo A, Ji X, Roberts LS, Louie SM, Mulvihill MM, et al. Ether
lipid generating enzyme AGPS alters the balance of structural and
signaling lipids to fuel cancer pathogenicity. Proc Natl Acad Sci U S A.
2013;110(37):14912–7.
40. Eisenmann KM, Dykema KJ, Matheson SF, Kent NF, DeWard AD, West RA, et al.
5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-
suppression network sensing actin dynamics. Oncogene. 2009;28(39):3429–41.
41. Nyakern M, Tazzari PL, Finelli C, Bosi C, Follo MY, Grafone T, et al. Frequent
elevation of Akt kinase phosphorylation in blood marrow and peripheral
blood mononuclear cells from high-risk myelodysplastic syndrome patients.
Leukemia. 2006;20(2):230–8.
42. Franco I, Gulluni F, Campa CC, Costa C, Margaria JP, Ciraolo E, et al. PI3K
class II alpha controls spatially restricted endosomal PtdIns3P and Rab11
activation to promote primary cilium function. Dev Cell. 2014;28(6):647–58.
43. Fuchs O, Provaznikova D, Kocova M, Kostecka A, Cvekova P, Neuwirtova R,
et al. CEBPA polymorphisms and mutations in patients with acute myeloid
leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin’s
lymphoma. Blood Cells Mol Dis. 2008;40(3):401–5.
44. Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M, et
al. A randomized phase 3 study of lenalidomide versus placebo in RBC
transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic
syndromes with del5q. Blood. 2011;118(14):3765–76.
45. Raza A, Mehdi M, Mumtaz M, Ali F, Lascher S, Galili N. Combination of
5-azacytidine and thalidomide for the treatment of myelodysplastic
syndromes and acute myeloid leukemia. Cancer. 2008;113(7):1596–604.
46. Sood R, Makalowska I, Carpten JD, Robbins CM, Stephan DA, Connors TD, et
al. The human RGL (RalGDS-like) gene: cloning, expression analysis and
genomic organization. Biochim Biophys Acta. 2000;1491(1-3):285–8.
47. Schenkova K, Lutz J, Kopp M, Ramos S, Rivero F. MUF1/leucine-rich repeat
containing 41 (LRRC41), a substrate of RhoBTB-dependent cullin 3 ubiquitin
ligase complexes, is a predominantly nuclear dimeric protein. J Mol Biol.
2012;422(5):659–73.
48. Maeda T, Yagasaki F, Ishikawa M, Takahashi N, Bessho M. Transforming
property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that
subsequently progressed to AML. Blood. 2005;105(5):2115–23.
49. Ross DD. Modulation of drug resistance transporters as a strategy for treating
myelodysplastic syndrome. Best Pract Res Clin Haematol. 2004;17(4):641–51.
50. Steimle V, Durand B, Barras E, Zufferey M, Hadam MR, Mach B, et al. A novel
DNA-binding regulatory factor is mutated in primary MHC class II deficiency
(bare lymphocyte syndrome). Genes Dev. 1995;9(9):1021–32.
51. Fukuda MN, Sato T, Nakayama J, Klier G, Mikami M, Aoki D, et al. Trophinin
and tastin, a novel cell adhesion molecule complex with potential
involvement in embryo implantation. Genes Dev. 1995;9(10):1199–210.
52. Bettermann K, Benesch M, Weis S, Haybaeck J. SUMOylation in carcinogenesis.
Cancer Lett. 2012;316(2):113–25.
53. Pan CL, Baum PD, Gu M, Jorgensen EM, Clark SG, Garriga G. C. elegans AP-2
and retromer control Wnt signaling by regulating mig-14/Wntless. Dev Cell.
2008;14(1):132–9.
54. Pavlaki K, Pontikoglou CG, Demetriadou A, Batsali AK, Damianaki A, Simantirakis E,
et al. Impaired proliferative potential of bone marrow mesenchymal stromal cells
in patients with myelodysplastic syndromes is associated with abnormal WNT
signaling pathway. Stem Cells Dev. 2014;23(14):1568–81.
55. Bar M, Stirewalt D, Pogosova-Agadjanyan E, Wagner V, Gooley T, Abbasi N,
et al. Gene expression patterns in myelodyplasia underline the role of
apoptosis and differentiation in disease initiation and progression. Transl
Oncogenomics. 2008;3:137–49.
56. Gal H, Amariglio N, Trakhtenbrot L, Jacob-Hirsh J, Margalit O, Avigdor A, et al.
Gene expression profiles of AML derived stem cells; similarity to hematopoietic
stem cells. Leukemia. 2006;20(12):2147–54.
57. Jamieson CH, Weissman IL, Passegue E. Chronic versus acute myelogenous
leukemia: a question of self-renewal. Cancer Cell. 2004;6(6):531–3.
58. Roversi FM, Lopes MR, Machado-Neto JA, Longhini AL, Duarte AS, Baratti MO, et
al. Serine protease inhibitor kunitz-type 2 is downregulated in myelodysplastic
syndromes and modulates cell-cell adhesion. Stem Cells Dev. 2014;23(10):1109–20.
59. Movafagh S, Crook S, Vo K. Regulation of hypoxia-inducible factor-1a by
reactive oxygen species: new developments in an old debate. J Cell
Biochem. 2015;116(5):696–703.
60. Arvanitis DA, Spandidos DA. Deregulation of the G1/S phase transition in
cancer and squamous intraepithelial lesions of the uterine cervix: a case
control study. Oncol Rep. 2008;20(4):751–60.
61. Saberwal G, Broderick E, Janssen I, Shetty V, Alvi S, Lisak L, et al. Involvement
of cyclin D1 and E2F1 in intramedullary apoptosis in myelodysplastic syndromes.
J Hematother Stem Cell Res. 2003;12(4):443–50.
62. Tong H, Hu C, Zhuang Z, Wang L, Jin J. Hypoxia-inducible factor-1alpha
expression indicates poor prognosis in myelodysplastic syndromes. Leuk
Lymphoma. 2012;53(12):2412–8.
63. Veraldi KL, Arhin GK, Martincic K, Chung-Ganster LH, Wilusz J, Milcarek C.
hnRNP F influences binding of a 64-kilodalton subunit of cleavage
stimulation factor to mRNA precursors in mouse B cells. Mol Cell Biol. 2001;
21(4):1228–38.
64. Boultwood J, Pellagatti A, Nikpour M, Pushkaran B, Fidler C, Cattan H, et al.
The role of the iron transporter ABCB7 in refractory anemia with ring
sideroblasts. PLoS One. 2008;3(4):e1970.
65. Mazzoccoli G, De CA, Piepoli A, Vinciguerra M. The circadian clock and the
hypoxic response pathway in kidney cancer. Tumour Biol. 2014;35(1):1–7.
66. Mazzoccoli G, Vinciguerra M, Papa G, Piepoli A. Circadian clock circuitry in
colorectal cancer. World J Gastroenterol. 2014;20(15):4197–207.
67. Maegawa S, Gough SM, Watanabe-Okochi N, Lu Y, Zhang N, Castoro RJ, et
al. Age-related epigenetic drift in the pathogenesis of MDS and AML.
Genome Res. 2014;24(4):580–91.
68. Baratti MO, Moreira YB, Traina F, Costa FF, Verjovski-Almeida S, Olalla-Saad
ST, et al. Identification of protein-coding and non-coding RNA expression
profiles in CD34+ and in stromal cells in refractory anemia with ringed
sideroblasts. BMC Med Genomics 2010;3:30.
69. Bhatia R, Deeg HJ. Treatment-related myelodysplastic syndrome: molecular
characteristics and therapy. Curr Opin Hematol. 2011;18(2):77–82.
70. Chapuis N, Tamburini J, Cornillet-Lefebvre P, Gillot L, Bardet V, Willems L, et
al. Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt
activation in acute myeloid leukemia: therapeutic value of neutralizing
anti-IGF-1R antibody. Haematologica. 2010;95(3):415–23.
71. Heredia FF, de Sousa JC, Ribeiro Junior HL, Carvalho AF, Magalhaes SM,
Pinheiro RF. Proteins related to the spindle and checkpoint mitotic
emphasize the different pathogenesis of hypoplastic MDS. Leuk Res. 2014;
38(2):218–24.
72. Khanna-Gupta A. Sumoylation and the function of CCAAT enhancer binding
protein alpha (C/EBP alpha). Blood Cells Mol Dis. 2008;41(1):77–81.
73. Maratheftis CI, Giannouli S, Spachidou MP, Panayotou G, Voulgarelis M. RNA
interference of interferon regulatory factor-1 gene expression in THP-1
cell line leads to toll-like receptor-4 overexpression/activation as well as
up-modulation of annexin-II. Neoplasia. 2007;9(12):1012–20.
74. Mjahed H, Girodon F, Fontenay M, Garrido C. Heat shock proteins in
hematopoietic malignancies. Exp Cell Res. 2012;318(15):1946–58.
75. Qi H, Xiao L, Lingyun W, Ying T, Yi-Zhi L, Shao-Xu Y, et al. Expression of
type 1 insulin-like growth factor receptor in marrow nucleated cells in
malignant hematological disorders: correlation with apoptosis. Ann
Hematol. 2006;85(2):95–101.
76. Sukhai MA, Prabha S, Hurren R, Rutledge AC, Lee AY, Sriskanthadevan S, et al.
Lysosomal disruption preferentially targets acute myeloid leukemia cells and
progenitors. J Clin Invest. 2013;123(1):315–28.
77. van der Putten K, Koch B, van Someren E, Wielders J, Ter Wee P, Nagtegaal
E, et al. The role of renal function loss on circadian misalignment of
cytokines EPO, IGF-1, IL-6 and TNF-alfa in chronic renal disease. Neuro
Endocrinol Lett. 2011;32(2):148–53.
Guerenne et al. Journal of Hematology & Oncology  (2016) 9:5 Page 19 of 20
78. Kogan SC, Ward JM, Anver MR, Berman JJ, Brayton C, Cardiff RD, et al.
Bethesda proposals for classification of nonlymphoid hematopoietic
neoplasms in mice. Blood. 2002;100(1):238–45.
79. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE.
RAG-1-deficient mice have no mature B and T lymphocytes. Cell.
1992;68(5):869–77.
80. Fan AC, Deb-Basu D, Orban MW, Gotlib JR, Natkunam Y, O'Neill R, et al.
Nanofluidic proteomic assay for serial analysis of oncoprotein activation in
clinical specimens. Nat Med. 2009;15(5):566–71.
81. de la Grange P, Dutertre M, Martin N, Auboeuf D. FAST DB: a website resource
for the study of the expression regulation of human gene products. Nucleic
Acids Res. 2005;33(13):4276–84.
82. de la Grange P, Gratadou L, Delord M, Dutertre M, Auboeuf D. Splicing factor
and exon profiling across human tissues. Nucleic Acids Res. 2010;38(9):2825–38.
83. de la Grange P, Dutertre M, Correa M, Auboeuf D. A new advance in
alternative splicing databases: from catalogue to detailed analysis of
regulation of expression and function of human alternative splicing variants.
BMC Bioinformatics. 2007;8:180.
84. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative
analysis of large gene lists using DAVID bioinformatics resources. Nat
Protoc. 2009;4(1):44–57.
85. Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools:
paths toward the comprehensive functional analysis of large gene lists.
Nucleic Acids Res. 2009;37(1):1–13.
86. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al.
PGC-1alpha-responsive genes involved in oxidative phosphorylation are
coordinately downregulated in human diabetes. Nat Genet. 2003;34(3):267–73.
87. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al.
Gene set enrichment analysis: a knowledge-based approach for
interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A.
2005;102(43):15545–50.
88. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al.
International scoring system for evaluating prognosis in myelodysplastic
syndromes. Blood. 1997;89(6):2079–88.
89. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al.
The 2008 revision of the World Health Organization (WHO) classification of
myeloid neoplasms and acute leukemia: rationale and important changes.
Blood. 2009;114(5):937–51.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Guerenne et al. Journal of Hematology & Oncology  (2016) 9:5 Page 20 of 20
